Restylane Lyft with Lidocaine

Restylane Lyft is part of a class of treatments called dermal fillers. These all work to treat wrinkles, but with different active ingredients.

Juvéderm another hyaluronic acid-containing dermal filler may also be compared with Restylane Lyft. They also both contain lidocaine. The primary differences between these two products is that Juvéderm can create results that last longer and are smoother in appearance.

You might talk to your provider about the differences between Restylane Lyft and Juvéderm Voluma if you’re interested in adding more volume to the cheek area.
How to find a provider

Your search for a Restylane Lyft provider may start online. It’s important to compare a few candidates, and to not just select the first provider you find.

Call prospective providers to set up consultations so that they may answer any questions you may have. This is also a good opportunity to ask about their credentials and look through their portfolios.

Restylane Lyft should be injected by a medical doctor only. This may include a board-certified plastic surgeon or dermatologist.

Precautions
 Restylane® Lyft with Lidocaine is packaged for single patient use. Do not resterilize. Do not use if package is opened or damaged.
 For the treatment of moderate to severe facial wrinkles and folds, the maximum recommended dose per treatment is 6.0 mL based on U.S. clinical studies. For cheek augmentation implantation and the treatment of age-related midface volume deficit in patients over the age of 21 the maximum recommended dose is also 6.0 mL per treatment. For the treatment of dorsal hand volume deficit, the maximum recommended dose per hand is 3.0 mL based on U.S. clinical studies. The safety of injection greater amounts has not been established.

 The safety or effectiveness of Restylane® Lyft with Lidocaine for the treatment of anatomic regions other than nasolabial folds, midface area and dorsal hand has not been established in controlled clinical studies.
 The safety and effectiveness of cannula injection of Restylane® Lyft with Lidocaine for cheek augmentation and correction of age-related midface contour deficiencies have only been clinically evaluated in three brands of blunt-tip cannulas (DermaSculpt, Softfil, and TSK Steriglide) that were 25G-27G and 1.5 or 2 inches in length.
 Long term safety and effectiveness of Restylane® Lyft with Lidocaine beyond one year have not been investigated in clinical trials.
 As with all transcutaneous procedures, Restylane® Lyft with Lidocaine implantation carries a risk of infection. Standard precautions associated with injectable materials should be followed.
 The safety and efficacy of Restylane® Lyft with Lidocaine for lip augmentation has not been established.
 The safety of Restylane® Lyft with Libing.com

ocaine for use during pregnancy, in breastfeeding females or in patients under 18 years has not been established.
 Formation of keloids may occur after dermal filler injections including Restylane® Lyft with Lidocaine ®. Keloid formation was not observed in studies involving 709 patients (including 160 African-Americans and 76 other patients of Fitzpatrick Skin Types IV, V and VI). For additional information please refer to Studies MA-1400-02, MA-1400-01, 31GE0002, 31GE0101, and MA-1400-05 in the Clinical Trials Section. In study MA-1400-03 with Restylane® Lyft with Lidocaine and Perlane®, there were 51.7% (31/60) of patients with Fitzpatrick Skin Types IV, V, and VI and no reports of keloid formation.
 Restylane® Lyft with Lidocaine injection may cause hyperpigmentation at the injection site. In a clinical study of 150 patients with pigmented skin (of African-American heritage and Fitzpatrick Skin Types IV, V, and VI), the incidence of post-inflammatory hyperpigmentation was 6% (9/150). 50% of these events lasted up to six weeks after initial implantation. In study MA-1400-03 with Perlane® and Restylane® Lyft with Lidocaine, there were 51.7% (31/60) of patients with Fitzpatrick Skin Types IV, V, and VI and no reports of hyperpigmentation. In study MA-1400-05 with Restylane® Lyft with Lidocaine, there were 30.5% (61/200) of patients with Fitzpatrick Skin Types IV, V, and VI and no reports of hyperpigmentation.
 Restylane® Lyft with Lidocaine should be used with caution in patients on immunosuppressive therapy.
 Use of Restylane® Lyft with Lidocaine in dorsal hand in patients with diseases, injuries or disabilities of the hand has not been studied. Care should be used in treating patients with autoimmune disease affecting the hand, hand implants, Dupuytren’s contracture, history of hand tumor, vascular malformations, Raynaud’s disease and patients at risk for tendon rupture.
 Bruising or bleeding may occur at Restylane® Lyft with Lidocaine injection sites. Restylane® Lyft with Lidocaine should be used with caution in patients who have undergone therapy with thrombolytics, anticoagulants, or inhibitors of platelet aggregation in the preceding 3 weeks.

 After use, syringes and needles/blunt cannula should be handled as potential biohazards. Disposal should be in accordance with accepted medical practice and applicable local, state, and federal requirements.
 The safety of Restylane® Lyft with Lidocaine with concomitant dermal therapies such as epilation, UV irradiation, or laser, mechanical or chemical peeling procedures has not been evaluated in controlled clinical trials.
 Patients should minimize exposure of the treated area to excessive sun, UV lamp exposure and extreme cold weather at least until any initial swelling and redness has resolved.
 If laser treatment, chemical peeling or any other procedure based on active dermal response is considered after treatment with Restylane® Lyft with Lidocaine, there is a possible risk of eliciting an inflammatory reaction at the implant site. This also applies if Restylane® Lyft with Lidocaine is administered before the skin has healed completely after such a procedure.
 Injection of Restylane® Lyft with Lidocaine into patients with a history of previous herpetic eruption may be associated with reactivation of the herpes.
 Restylane® Lyft with Lidocaine is a clear, colorless gel without particulates. In the event that the content of a syringe shows signs of separation and/or appears cloudy, do not use the syringe and notify Galderma Laboratories, L.P. at 1-855-425-8722. Glass is also subject to breakage under a variety of unavoidable conditions. Care should be taken with the handling of the glass syringe and with disposing of broken glass to avoid laceration or other injury.
 Restylane® Lyft with Lidocaine should not be mixed with other products before implantation of the device.
 Cheek augmentation or correction of age-related midface contour deficiencies in patients over the age of 21,with Restylane® Lyft with Lidocaine should only be performed by physicians who have appropriate experience and who are knowledgeable about the anatomy and the product for use in deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation.
 Correction of volume deficit in the dorsal hand in patients over the age of 21, with Restylane® Lyft with Lidocaine should only be performed by physicians who have appropriate experience and who are knowledgeable about the anatomy and the product for use in the subcutaneous plane.
 Safety of Restylane® Lyft with Lidocaine injected into the dorsum of the hand in patients under 22 years old has not been studied.
 In order to minimize the risks of potential complications, this product should only be used by health care practitioners who have appropriate training, experience, and who are knowledgeable about the anatomy at and around the site of injection.
 Health care practitioners are encouraged to discuss all potential risks of soft tissue injection with their patients prior to treatment and ensure that patients are aware of signs and symptoms of potential complications.
 The safety or effectiveness of Restylane® Lyft with Lidocaine for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds, with a small bore, blunt tip cannula has not been established in controlled clinical studies.

 The safety or effectiveness of Restylane® Lyft with Lidocaine for correction of volume deficit in the dorsal hand, with a small bore, blunt tip cannula has not been established in controlled clinical studies.
Adverse Experiences
Restylane® Lyft with Lidocaine is indicated for implantation into the deep dermis to superficial subcutis for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds and for subcutaneous to supraperiosteal implantation for cheek augmentation and correction of age- related midface contour deficiencies in patients over the age of 21. It is also indicated for injection into the subcutaneous plane in the dorsal hand to correct volume deficit in patients over the age of 21. Adverse event information for Restylane® Lyft with Lidocaine use in the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds. and for cheek augmentation and correction of age-related midface contour deficiencies. Adverse event information for Restylane® Lyft with Lidocaine using a small bore, blunt-tip cannula for subcutaneous to supraperiosteal implantation for cheek augmentation and correction of age-related midface contour deficiencies in patients over the age of 21.Adverse event information for Restylane Lyft with Lidocaine use in the dorsal hand to correct volume deficit.
Restylane® Lyft with Lidocaine for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds.
There were five US studies that reported adverse events in support of the indication for treatment of moderate to severe facial folds and wrinkles, such as nasolabial folds.
In two U.S. studies (i.e., Study MA-1400-01 and Study MA-1400-02) involving 433 patients at 25 centers, the adverse outcomes reported in patient diaries during 14 days after treatment are presented in Tables 1–4. The physician diagnosed adverse events identified in these studies at 72 hours after injection are presented in Table 7. In Study MA-1400-01, 150 patients were injected with Perlane® on one side of the face and Restylane® on the other side of the face. In study MA- 1400-02, 283 patients were randomized to receive either Perlane® or Restylane® injection on both sides of the face. Table 8 presents all investigator-identified adverse events recorded at study visits 2 weeks or more after injection in studies MA-1400-01, MA-1400-02, 31GE0101 and 31GE0002. In Study 31GE0101, 150 Canadian patients were injected with both Perlane® and Hylaform®. In Study 31GE0002, 68 Scandinavian patients underwent both Perlane® and Zyplast® injections.
In a fifth U.S. study (Study MA-1400-03) 60 patients at three centers randomly received Restylan.